1. HBW Insight
  2. >>Health
  3. >>Rx-to-OTC Switch

Change At White House And Proof Of User Fees’ Value: ‘ACNU’ Final Rule Publication Drivers?

(Source: Shutterstock/Citeline)

Either the clock was ticking or the sands in the hourglass were dwindling before the recent publication of a US regulation to allow sales of OTC drugs using digital labeling for consumers’ self-selection of “additional conditions for nonprescription use” more than a decade after the Food and Drug Administration suggested the change.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rx-to-OTC Switch

Preamble ‘Poison Pill’ Could Haunt ACNU Switch Rule – House Energy And Commerce Members

 
• By Malcolm Spicer

Reps. Latta, Crenshaw and Miller-Meeks contend language in ACNU final rule preamble would allow a sponsor of an approved application to litigate to halt Rx availability of same formulation and “risk eliminating the very rule on which its product approval was based.”

Over The Counter: Evolving The UK Consumer Health Industry, With PAGB’s Michelle Riddalls

 
• By David Ridley

HBW Insight catches up with PAGB CEO Michelle Riddalls to chat about the association's new five year plan. Riddalls also reflects on the successes of the last five years, including relaunching the UK Reclassification Alliance, which has published a list of Rx-to-OTC switches the government would like to see applications for. Part one of two.

Arkansas Law For OTC Ivermectin Sales Doesn’t Answer Dose, Format And Access Questions

 
• By Malcolm Spicer

“I’m not sure exactly if they understood how broad this actually is and what that might potentially lead to or what the follow-up would be if somebody now decides to sell a 10-milligram version of ivermectin for human use,” says food and drug regulation attorney Frederick Stearns.

Eisai Switches Proton Pump Inhibitor Rabeprazole To OTC In Japan

 
• By David Ridley

Eisai aims to support people in Japan with severe heartburn and discomfort caused by gastric acid related conditions by switching from prescription to OTC status its Pariet-branded proton pump inhibitor.

More from HBW Insight

US FDA Layoffs Expected To Have Ripple Effect On Cosmetics Office Functions

 
• By Lauren Nardella

Functions supporting the US Food and Drug Administration’s Office of Cosmetics and Colors have been impacted by the reduction-in-force.

Australia’s Wellnex Life Poised To Enter UK’s CHC Market

 
• By Tom Gallen

Wellnex bringing brands such as Pain Away, Wakey Wakey and Nighty Night to UK market shortly after gaining admission to the the AIM market of the London Stock Exchange.

US FDA Allows Telework For Reviewers As Companies Detail Layoff-Related Problems

 
• By Derrick Gingery

The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.